Viridian Therapeutics (NASDAQ:VRDN) Sees Large Volume Increase

Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) saw an uptick in trading volume on Friday . 411,187 shares changed hands during trading, a decline of 55% from the previous session's volume of 923,307 shares.The stock last traded at $15.40 and had previously closed at $15.16.

Analysts Set New Price Targets

Several research firms have recently weighed in on VRDN. Wedbush raised their price objective on Viridian Therapeutics from $39.00 to $40.00 and gave the stock an "outperform" rating in a research note on Wednesday, February 28th. HC Wainwright reissued a "buy" rating and set a $37.00 price objective on shares of Viridian Therapeutics in a research note on Thursday, February 29th. Needham & Company LLC reissued a "buy" rating and set a $30.00 price objective on shares of Viridian Therapeutics in a research note on Wednesday, March 20th. Finally, B. Riley reduced their price objective on Viridian Therapeutics from $29.00 to $25.00 and set a "buy" rating for the company in a research note on Thursday, March 21st. Ten analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $36.60.

Viridian Therapeutics Trading Down 3.7 %

The firm has a market cap of $916.44 million, a price-to-earnings ratio of -2.74 and a beta of 1.07. The company has a 50-day moving average price of $17.70 and a 200 day moving average price of $17.51. The company has a quick ratio of 18.26, a current ratio of 18.26 and a debt-to-equity ratio of 0.09.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last issued its earnings results on Tuesday, February 27th. The company reported ($1.35) EPS for the quarter, missing the consensus estimate of ($0.98) by ($0.37). The business had revenue of $0.07 million during the quarter, compared to analyst estimates of $0.15 million. Viridian Therapeutics had a negative return on equity of 121.80% and a negative net margin of 75,711.48%. The business's quarterly revenue was down 31.4% on a year-over-year basis. During the same period last year, the business earned ($1.13) EPS. As a group, research analysts anticipate that Viridian Therapeutics, Inc. will post -4.39 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Fairmount Funds Management Llc acquired 476,190 shares of the business's stock in a transaction that occurred on Monday, January 22nd. The stock was acquired at an average cost of $21.00 per share, for a total transaction of $9,999,990.00. Following the completion of the acquisition, the director now owns 1,839,954 shares in the company, valued at $38,639,034. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 1.43% of the stock is owned by corporate insiders.

Institutional Trading of Viridian Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. raised its holdings in Viridian Therapeutics by 43.2% during the first quarter. JPMorgan Chase & Co. now owns 18,666 shares of the company's stock valued at $345,000 after buying an additional 5,633 shares in the last quarter. Citigroup Inc. raised its holdings in Viridian Therapeutics by 89.1% during the first quarter. Citigroup Inc. now owns 28,140 shares of the company's stock valued at $520,000 after buying an additional 13,256 shares in the last quarter. Bank of Montreal Can bought a new position in Viridian Therapeutics during the first quarter valued at about $414,000. Vanguard Group Inc. raised its holdings in Viridian Therapeutics by 1.6% during the first quarter. Vanguard Group Inc. now owns 940,577 shares of the company's stock valued at $17,391,000 after buying an additional 14,901 shares in the last quarter. Finally, Affinity Asset Advisors LLC bought a new position in Viridian Therapeutics during the first quarter valued at about $925,000.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.